PROZAC by Eli Lilly and Company is unknown, it is presumed to be linked to its inhibition of cns neuronal uptake of serotonin. Approved for depressive episodes associated with bipolar i disorder, the treatment of treatment resistant depression. First approved in 1999.
Drug data last refreshed 2d ago · AI intelligence enriched 1mo ago
PROZAC (fluoxetine hydrochloride) is an oral small-molecule tablet approved by the FDA on March 9, 1999, for the treatment of depressive episodes associated with Bipolar I Disorder and treatment-resistant depression. The drug is presumed to work through inhibition of CNS neuronal uptake of serotonin, though its exact mechanism of action remains incompletely understood. As a selective serotonin reuptake inhibitor (SSRI), it represents a foundational pharmacotherapy in psychiatric treatment and remains widely prescribed despite the emergence of newer alternatives.
unknown, it is presumed to be linked to its inhibition of CNS neuronal uptake of serotonin.
To Demonstrate the Relative Bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Healthy Adult Males Under Fasting Conditions
To Demonstrate the Relative Bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Healthy Adult Males Under Fed and Fasted Conditions
Worked on PROZAC at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moPROZAC currently has zero linked job openings, reflecting the product's mature lifecycle and reduced commercial development activity. Roles on this product would primarily involve generic defense, managed care contracting, and cost-management strategies rather than new indication launches. Critical skills include deep knowledge of psychiatric treatment algorithms, formulary management, and expertise in competing on outcomes and real-world evidence as pricing pressures intensify.